CD274 and neoplasm: Specifically, patients with PD-L1-positive tumours underwent a dose-escalation study using intravenous camrelizumab (3 mg/kg, every 2 weeks), along with intravenous infusion of T cells and dendritic cells (DCs) every 27–36 days.